Companies › Jiangsu Aidea Pharmaceutical Group
3 active drug programs in 4 registered trials: 4 Phase 1; Other, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADB116 for Injection | – | Phase 1 | Healthy Adult Participants | Dec 2026 |
| ACC017 Non-nucleoside reverse transcriptase inhibitor (NNRTI) | – | Phase 1 | Infection, Human Immunodeficiency Virus | Jun 2027 |
| ACC085 Injection | – | Phase 1 | Healthy Adult Participants | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07729839 | ADB116 for Injection | Phase 1 | Healthy Adult Participants | Other | Dec 2026 |
| NCT07711210 | ACC017 | Phase 1 | Infection, Human Immunodeficiency Virus | Infectious disease | Jun 2027 |
| NCT07835633 | ACC085 Injection | Phase 1 | Healthy Adult Participants | Other | Jul 2028 |
| NCT07711223 | ACC017 | Phase 1 | Infection, Human Immunodeficiency Virus | Infectious disease | Aug 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.